Optiscan has been featured in Stockhead, The Australian and 11 News Corp mastheads following the announcement of a milestone three-year collaboration with Australian Clinical Labs (ACL) to advance the adoption and commercial readiness of the company’s InForm™ digital pathology platform.

“It gives us access to a fully operational pathology laboratory that will quicken the pace at which we validate the InForm device in real-world conditions, ensuring it meets the needs of healthcare sector professionals, pathologists and technicians,” said Dr Camile Farah, Optiscan CEO and Managing Director.

“Then there is the regulatory approvals-related advantage delivered by the agreement. It will help expedite our plans to build an image databank of human tissues and associated pathologies, a useful data collection resource that will be incorporated into preparatory work we are now undertaking for regulatory submissions in Australia and in the US.”

“I want to personally thank ACL for sharing in this vision,” he said. “I am confident that this agreement will deliver outcomes that demonstrate the significant efficiencies in pathology services encapsulated in our digital solution.”

ACL’s Medical Director and Chief Pathologist, Associate Professor Tony Landgren, said: “This opportunity has the potential to enhance diagnostic workflows with real-time, data-driven insights — a move that supports faster, more accurate decision-making.”

Stockhead – Read the full article here